NCT04705350View on ClinicalTrials.gov

A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

July 28, 2021

Study Completion Date

July 28, 2021

Conditions
Healthy Study Participants
Interventions
DRUG

Zampilimab

Participants will receive a single intravenous dose of zampilimab at a pre-specified time point.

DRUG

Placebo

Participants will receive matching placebo at a pre-specified time point to maintain the blinding.

Trial Locations (1)

Unknown

Up0105 001, London

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY

NCT04705350 - A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants | Biotech Hunter | Biotech Hunter